Study the immune responses after pertussis vaccination in adults

Gepubliceerd: 07-04-2014 Laatst bijgewerkt: 15-05-2024

The main purpose of this study is to investigate the longitudinal effects of an aP booster vaccination in adults, on long-term humoral and cellular memory immunity against B. pertussis. By measuring antibody levels against the various pertussis...

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON28859

Bron
Nationaal Trial Register

Verkorte titel
VIKING-studie

Aandoening

Whooping cough, pertussis, vaccination, cellular immunity, humoral immunity

Ondersteuning

Primaire sponsor: Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
Overige ondersteuning: Rijksinstituut voor Volksgezondheid en Milieu (RIVM)

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

• To assess pertussis specific IgG antibody levels in serum at T0 (prior to vaccination), 14 days (T1), 28 days (T2), 1 year (T3) and 2 (T4) years after vaccination to determine the

kinetics of pertussis specific antibody levels after an aP booster vaccination in adults 25-29 years of age;
• To assess memory B- and T-cell responses against the various B. pertussis vaccine proteins at all time points to determine the effects of an aP booster vaccination in adults 25-29 years of age.

Toelichting onderzoek

Achtergrond van het onderzoek

Pertussis, or whooping cough, is caused by the bacterium Bordetella pertussis and is an acute and serious respiratory
infection, in particular for young and unvaccinated children. Since the introduction of whole-cell pertussis (wP) vaccines in
1953 in the Netherlands, the incidence of pertussis in childhood reduced rapidly. However, despite high vaccination
coverage (95%), pertussis is re-emerging in the Netherlands since 1996. This phenomenon is also observed in most other
western countries with high vaccination coverage. The most recent epidemic in 2012 in the Netherlands highlighted the
vulnerability of infants for a pertussis infection since three infants died. Vaccine derived protection against pertussis is not
yet established in the first months of life. The pertussis incidence in adults increases as well. Prolonged cough episodes is
one of the symptoms adults suffer from.
The main purpose of this study is to investigate the longitudinal effects of an aP booster vaccination in adults, on longterm
humoral and cellular memory immunity against B. pertussis. By measuring antibody levels against the various
pertussis proteins, antibody kinetics in serum and saliva can be determined. These insights are necessary to understand
the possible effects of an adult aP booster vaccination on long-term immunity against pertussis. If the decay of vaccine
induced antibody levels is limited for a long period, these antibodies could help protect an infant when antibodies cross the
placenta during pregnancy.

Doel van het onderzoek

The main purpose of this study is to investigate the longitudinal effects of an aP booster vaccination in adults, on long-term humoral and cellular memory immunity against B. pertussis. By measuring antibody levels against the various pertussis proteins, antibody kinetics in serum and saliva can be determined. In addition, if the decay of vaccine induced antibody levels is limited for a long period in women, these antibodies could help protect an

infant when specific pertussis antibodies are transported across the placenta during pregnancy.

Onderzoeksopzet

T0 (prior to vaccination), 14 days (T1), 28 days (T2), 1 year (T3) and 2 (T4) years after vaccination

Onderzoeksproduct en/of interventie

Single vaccination with Tdap at first study visit. 5 blood- and saliva-sample collections. before vaccination, two weeks, four weeks, one year and two years after vaccination.

Contactpersonen

Publiek

Postbus 1

Saskia Lee, van der
Bilthoven 3720 BA
The Netherlands
033-2743407

Wetenschappelijk

Postbus 1

Saskia Lee, van der
Bilthoven 3720 BA
The Netherlands
033-2743407

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

• Good general health;

• 25-29 years of age;

• Vaccinated with DTwP-IPV (RIVM) at 3, 4, 5, and 11 months of age;

• Received all other regular vaccines according to the Dutch NIP;

• Provision of written informed consent;

• Adherent to protocol and available during the study period.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

• Antibiotic use within 14 days of enrollment;

• Present evidence of serious disease(s) demanding immunosuppressive medical treatment, like corticosteroids, that might interfere with the results of the study within the last 3 months;

•Known or suspected allergy to any of the vaccine components (by medical history);

• Occurrence of serious adverse event after primary DTwP-IPV vaccination or other vaccination (by medical history);

• Known or suspected immune deficiency;

• History of any neurologic disorder, including epilepsy;

• Previous administration of serum products (including immunoglobulins) within 6 months before vaccination and blood/ saliva sampling;

• Vaccination with any other pertussis vaccine than those described in the inclusion criteria;

• No DT or DT-IPV vaccination at least 5 years before enrollment;

• Vaccination within a month before enrollment;

• Pregnant at start of study (when vaccination is administered)

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blindering:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland

Status:	Werving nog niet gestart
(Verwachte) startdatum:	21-04-2014
Aantal proefpersonen:	100
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum:	07-04-2014
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 50704
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL4256
NTR-old	NTR4494
CCMO	NL47382.094.13
OMON	NL-OMON50704

Resultaten

Samenvatting resultaten
N/A